Resveratrol suppresses PAI-1 gene expression in a human in vitro model of inflamed adipose tissue

Oxidative Medicine and Cellular Longevity

Volumn , Issue , 2013, Pages

  Zagotta, Ivana ^a   Dimova, Elitsa Y ^b   Funcke, Jan Bernd ^a   Wabitsch, Martin ^a   Kietzmann, Thomas ^b   Fischer Posovszky, Pamela ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOSE TISSUE; CONCENTRATION-DEPENDENT MANNERS; HUMAN ADIPOSE TISSUE; IN-VITRO MODELS; INFLAMMATORY CONDITIONS; PATHOPHYSIOLOGICAL; PLASMINOGEN ACTIVATOR INHIBITOR-1; SIGNALING COMPONENTS;

GENE EXPRESSION; NUTRITION; TISSUE;

RESVERATROL;

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN METABOLITE; RESVERATROL; SIRTUIN 1; TRANSCRIPTION FACTOR NRF2; DNA; STILBENE DERIVATIVE;

ADIPOCYTE; ADIPOSE TISSUE; ADIPOSE TISSUE INFLAMMATION; ANIMAL CELL; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INFLAMMATION; MOUSE; NONHUMAN; OBESITY; SIGNAL TRANSDUCTION; SIMPSON GOLABI BEHMEL SYNDROME; UPREGULATION; ANIMAL; BIOLOGICAL MODEL; CONGENITAL HEART MALFORMATION; CULTURE MEDIUM; DOWN REGULATION; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; GIGANTISM; HEART ARRHYTHMIA; INTELLECTUAL IMPAIRMENT; METABOLISM; PATHOLOGY; PROTEIN BINDING; TIME; X CHROMOSOME LINKED DISORDER;

ADIPOCYTES; ADIPOSE TISSUE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ARRHYTHMIAS, CARDIAC; CULTURE MEDIA, CONDITIONED; DNA; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENETIC DISEASES, X-LINKED; GIGANTISM; HEART DEFECTS, CONGENITAL; HUMANS; INFLAMMATION; INTELLECTUAL DISABILITY; MICE; MODELS, BIOLOGICAL; NF-E2-RELATED FACTOR 2; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASES; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN BINDING; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; SIRTUIN 1; STILBENES; TIME FACTORS; UP-REGULATION;

EID: 84879382194     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2013/793525     Document Type: Article

References (100)

1. De Ferranti S. D., Osganian S. K., Epidemiology of paediatric metabolic syndrome and type 2 diabetes mellitus. Diabetes and Vascular Disease Research 2007 4 4 285 296
2. de Hamsten A., Walldius G., Dahlen G., Szamosi A., Landou C., Blomback M., Wiman B., Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. The Lancet 1987 2 8549 3 9 2-s2.0-0023185776
3. Juhan-Vague I., Roul C., Alessi M. C., Ardissone J. P., Heim M., Vague P., Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients: relationship with plasma insulin. Thrombosis and Haemostasis 1989 61 3 370 373 2-s2.0-0024327968
4. Schneider D. J., Nordt T. K., Sobel B. E., Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes 1993 42 1 1 7 2-s2.0-0027454614
5. Juhan-Vague I., Alessi M. C., PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thrombosis and Haemostasis 1997 78 1 656 660 2-s2.0-0030764551
6. Dellas C., Loskutoff D. J., Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Journal of Thrombosis and Haemostasis 2005 93 631 640
7. Lijnen H. R., Nelles L., Van Hoef B., Demarsin E., Collen D., Characterization of a chimeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator and amino acids 138 to 411 of single-chain urokinase-type plasminogen activator. Journal of Biological Chemistry 1988 263 35 19083 19091 2-s2.0-0024208745
8. Kohler H. P., Grant P. J., Plasminogen-activator inhibitor type 1 and coronary artery disease. The New England Journal of Medicine 2000 342 24 1792 1801 2-s2.0-0034660437 10.1056/NEJM200006153422406
9. Lund L. R., Georg B., Nielsen L. S., Mayer M., Dano K., Andreasen P. A., Plasminogen activator inhibitor type 1: cell-specific and differentiation- induced expression and regulation in human cell lines, as determined by enzyme-linked immunosorbent assay. Molecular and Cellular Endocrinology 1988 60 1 43 53 2-s2.0-0023692212
10. Dimova E. Y., Möller U., Herzig S., Fink T., Zachar V., Ebbesen P., Kietzmann T., Transcriptional regulation of plasminogen activator inhibitor-I expression by insulin-like growth factor-I via MAP kinases and hypoxia-inducible factor-I in HepG2 cells. Thrombosis and Haemostasis 2005 93 6 1176 1184 2-s2.0-20444480218 10.1160/TH04-11-0761
11. Kietzmann T., Roth U., Jungermann K., Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. Blood 1999 94 12 4177 4185 2-s2.0-0032795850
12. Kietzmann T., Samoylenko A., Roth U., Jungermann K., Hypoxia-inducible factor-1 and hypoxia response elements mediate the induction of plasminogen activator inhibitor-1 gene expression by insulin in primary rat hepatocytes. Blood 2003 101 3 907 914 2-s2.0-0037307621 10.1182/blood-2002-06-1693
13. Dimova E. Y., Kietzmann T., The MAPK pathway and HIF-1 are involved in the induction of the human PAI-1 gene expression by insulin in the human hepatoma cell line HepG2. Annals of the New York Academy of Sciences 2006 1090 355 367
14. Dimova E. Y., Kietzmann T., Metabolic, hormonal and environmental regulation of plasminogen activator inhibitor-1 (PAI-1) expression: lessons from the liver. Thrombosis and Haemostasis 2008 100 6 992 1006 2-s2.0-57349117608 10.1160/TH08-07-0490
15. Gonzalez M., del Mar B. M., Pons A., Llompart I., Tur J. A., Inflammatory markers and metabolic syndrome among adolescents. European Journal of Clinical Nutrition 2012 66 1141 1145
16. Samad F., Loskutoff D. J., Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Molecular Medicine 1996 2 5 568 582 2-s2.0-0029827134
17. Cigolini M., Targher G., Bergamo A. I., Tonoli M., Agostino G., De Sandre G., Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arteriosclerosis, Thrombosis, and Vascular Biology 1996 16 368 374
18. Vague P., Juhan-Vague I., Chabert V., Alessi M. C., Atlan C., Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. Metabolism 1989 38 9 913 915 2-s2.0-0024451095
19. Landin K., Stigendal L., Eriksson E., Krotkiewski M., Risberg B., Tengborn L., Smith U., Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 1990 39 10 1044 1048 2-s2.0-0025134778 10.1016/0026-0495(90)90164-8
20. McGill J. B., Schneider D. J., Arfken C. L., Lucore C. L., Sobel B. E., Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994 43 1 104 109 2-s2.0-0028008336
21. Eriksson P., Reynisdottir S., Lönnqvist F., Stemme V., Hamsten A., Arner P., Adipose tissue secretion of plasminogen activator inhibitor-1 in non- obese and obese individuals. Diabetologia 1998 41 1 65 71 2-s2.0-0031882421 10.1007/s001250050868
22. Samad F., Loskutoff D. J., The fat mouse: a powerful genetic model to study elevated plasminogen activator inhibitor 1 in obesity/NIDDM. Thrombosis and Haemostasis 1997 78 1 652 655 2-s2.0-0030805628
23. Skurk T., Hauner H., Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. International Journal of Obesity 2004 28 1357 1364 10.1038/sj.ijo.0802778
24. Ma L., Mao S., Taylor K. L., Kanjanabuch T., Guan Y., Zhang Y., Brown N. J., Swift L. L., McGuinness O. P., Wasserman D. H., Vaughan D. E., Fogo A. B., Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004 53 2 336 346 2-s2.0-10744228409 10.2337/diabetes.53.2.336
25. Hoffstedt J., Andersson I., Persson L., Isaksson B., Arner P., The common-675 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is strongly associated with obesity. Diabetologia 2002 45 4 584 587 2-s2.0-0035988198 10.1007/s00125-001-0774-5
26. Folsom A. R., Qamhieh H. T., Wing R. R., Jeffery R. W., Stinson V. L., Kuller L. H., Wu K. K., Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arteriosclerosis and Thrombosis 1993 13 2 162 169 2-s2.0-0027530758
27. Alessi M. C., Juhan-Vague I., PAI-1 and the metabolic syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 2200 2207
28. Signorelli P., Ghidoni R., Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. Journal of Nutritional Biochemistry 2005 16 8 449 466 2-s2.0-22844450866 10.1016/j.jnutbio.2005.01.017
29. Baur J. A., Pearson K. J., Price N. L., Jamieson H. A., Lerin C., Kalra A., Prabhu V. V., Allard J. S., Lopez-Lluch G., Lewis K., Pistell P. J., Poosala S., Becker K. G., Boss O., Gwinn D., Wang M., Ramaswamy S., Fishbein K. W., Spencer R. G., Lakatta E. G., Le Couteur D., Shaw R. J., Navas P., Puigserver P., Ingram D. K., De Cabo R., Sinclair D. A., Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006 444 7117 337 342 2-s2.0-33751072349 10.1038/nature05354
30. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., Messadeq N., Milne J., Lambert P., Elliott P., Geny B., Laakso M., Puigserver P., Auwerx J., Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1 Cell 2006 127 6 1109 1122 2-s2.0-33845399894 10.1016/j.cell.2006.11.013
31. Pearson K. J., Baur J. A., Lewis K. N., Peshkin L., Price N. L., Labinskyy N., Swindell W. R., Kamara D., Minor R. K., Perez E., Jamieson H. A., Zhang Y., Dunn S. R., Sharma K., Pleshko N., Woollett L. A., Csiszar A., Ikeno Y., Le Couteur D., Elliott P. J., Becker K. G., Navas P., Ingram D. K., Wolf N. S., Ungvari Z., Sinclair D. A., de Cabo R., Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metabolism 2008 8 2 157 168 2-s2.0-48349144852 10.1016/j.cmet.2008.06.011
32. Barger J. L., Kayo T., Vann J. M., Arias E. B., Wang J., Hacker T. A., Wang Y., Raederstorff D., Morrow J. D., Leeuwenburgh C., Allison D. B., Saupe K. W., Cartee G. D., Weindruch R., Prolla T. A., A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS ONE 2008 3 6 2-s2.0-48349110303 10.1371/journal.pone.0002264 e2264
33. Sun C., Zhang F., Ge X., Yan T., Chen X., Shi X., Zhai Q., SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metabolism 2007 6 4 307 319 2-s2.0-34548857700 10.1016/j.cmet.2007.08.014
34. Aubin M. C., Lajoie C., Clement R., Gosselin H., Calderone A., Perrault L. P., Female rats fed a high-fat diet were associated with vascular dysfunction and cardiac fibrosis in the absence of overt obesity and hyperlipidemia: therapeutic potential of resveratrol. Journal of Pharmacology and Experimental Therapeutics 2008 325 961 968
35. Shang J., Chen L., Xiao F., Sun H., Ding H., Xiao H., Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacologica Sinica 2008 29 6 698 706 2-s2.0-44849131936 10.1111/j.1745-7254.2008.00807.x
36. Shang J., Chen L., Xiao F., Resveratrol improves high-fat induced nonalcoholic fatty liver in rats. Chinese Journal of Hepatology 2008 16 8 616 619 2-s2.0-77952322358
37. Rocha K. K., Souza G. A., Ebaid G. X., Seiva F. R., Cataneo A. C., Novelli E. L., Resveratrol toxicity: effects on risk factors for atherosclerosis and hepatic oxidative stress in standard and high-fat diets. Food and Chemical Toxicology 2009 47 6 1362 1367
38. Rivera L., Morón R., Zarzuelo A., Galisteo M., Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochemical Pharmacology 2009 77 6 1053 1063 2-s2.0-60949087943 10.1016/j.bcp.2008.11.027
39. Ramadori G., Gautron L., Fujikawa T., Vianna C. R., Elmquist J. K., Coppari R., Central administration of resveratrol improves diet-induced diabetes. Endocrinology 2009 150 12 5326 5333 2-s2.0-71949100263 10.1210/en.2009-0528
40. Timmers S., Konings E., Bilet L., Houtkooper R. H., Van De Weijer T., Goossens G. H., Hoeks J., Van Der Krieken S., Ryu D., Kersten S., Moonen-Kornips E., Hesselink M. K. C., Kunz I., Schrauwen-Hinderling V. B., Blaak E. E., Auwerx J., Schrauwen P., Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metabolism 2011 14 5 612 622 2-s2.0-80455143206 10.1016/j.cmet.2011.10.002
41. Tome-Carneiro J., Gonzalvez M., Larrosa M., Yanez-Gascon M. J., Garcia-Almagro F. J., Ruiz-Ros J. A., Tomas-Barberan F. A., Garcia-Conesa M. T., Espin J. C., Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease. Cardiovascular Drugs and Therapy 2013 27 1 37 48
42. Poulsen M. M., Vestergaard P. F., Clasen B. F., Radko Y., Christensen L. P., Stodkilde-Jorgensen H., Moller N., Jessen N., Pedersen S. B., Jorgensen J. O., An investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013 62 4 1186 1195
43. Fischer-Posovszky P., Newell F. S., Wabitsch M., Tornqvist H. E., Human SGBS cells: a unique tool for studies of human fat cell biology. Obesity Facts 2008 1 4 184 189 2-s2.0-77954302595 10.1159/000145784
44. Hauner H., Skurk T., Wabitsch M., Cultures of human adipose precursor cells. Methods in Molecular Biology 2001 155 239 247 2-s2.0-0035222334
45. Kotnik P., Keuper M., Wabitsch M., Fischer-Posovszky P., Interleukin-1beta downregulates RBP4 secretion in human adipocytes. PLoS One 2013 8 e57796
46. Laderoute K. R., Amin K., Calaoagan J. M., Knapp M., Le T., Orduna J., Foretz M., Viollet B., 5′-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Molecular and Cellular Biology 2006 26 14 5336 5347 2-s2.0-33745840203 10.1128/MCB.00166-06
47. Livak K. J., Schmittgen T. D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001 25 4 402 408
48. Gregor M. F., Hotamisligil G. S., Inflammatory mechanisms in obesity. Annual Review of Immunology 2011 29 415 445
49. Keuper M., Dzyakanchuk A., Amrein K. E., Wabitsch M., Fischer-Posovszky P., THP-1 macrophages and SGBS adipocytes: a new human in vitro model system of inflamed adipose tissue. Frontiers in Endocrinology 2011 2 89
50. Picard F., Kurtev M., Chung N., Topark-Ngarm A., Senawong T., Machado De Oliveira R., Leid M., McBurney M. W., Guarente L., Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR- γ Nature 2004 429 771 776 2-s2.0-4344640637
51. Fischer-Posovszky P., Kukulus V., Tews D., Unterkircher T., Debatin K. M., Fulda S., Wabitsch M., Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner. The American Journal of Clinical Nutrition 2010 92 5 15
52. Wang A., Liu M., Liu X., Dong L. Q., Glickman R. D., Slaga T. J., Zhou Z., Liu F., Up-regulation of adiponectin by resveratrol: the essential roles of the Akt/FOXO1 and amp-activated protein kinase signaling pathways and DsbA-L. Journal of Biological Chemistry 2011 286 1 60 66 2-s2.0-78650929972 10.1074/jbc.M110.188144
53. Chen S., Li Z., Li W., Shan Z., Zhu W., Resveratrol inhibits cell differentiation in 3T3-L1 adipocytes via activation of AMPK. Canadian Journal of Physiology and Pharmacology 2011 89 11 793 799 10.1139/Y11-077
54. Lasa A., Schweiger M., Kotzbeck P., Churruca I., Simon E., Zechner R., Portillo M. P., Resveratrol regulates lipolysis via adipose triglyceride lipase. The Journal of Nutritional Biochemistry 2012 23 4 379 384
55. Mader I., Wabitsch M., Debatin K., Fischer-Posovszky P., Fulda S., Identification of a novel proapoptotic function of resveratrol in fat cells: SIRT1-independent sensitization to TRAIL-induced apoptosis. FASEB Journal 2010 24 6 1997 2009 2-s2.0-77953521260 10.1096/fj.09-142943
56. Miranda S., González-Rodríguez A., Revuelta-Cervantes J., Rondinone C. M., Valverde A. M., Beneficial effects of PTP1B deficiency on brown adipocyte differentiation and protection against apoptosis induced by pro- and anti-inflammatory stimuli. Cellular Signalling 2010 22 4 645 659 2-s2.0-74449087655 10.1016/j.cellsig.2009.11.019
57. Kang L., Heng W., Yuan A., Baolin L., Fang H., Resveratrol modulates adipokine expression and improves insulin sensitivity in adipocytes: relative to inhibition of inflammatory responses. Biochimie 2010 92 7 789 796 2-s2.0-77953536163 10.1016/j.biochi.2010.02.024
58. Esposito K., Ciotola M., Giugliano D., Rosiglitazone cools down inflammation in the metabolic syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 26 1413 1414
59. Fernández-Sánchez A., Madrigal-Santillán E., Bautista M., Esquivel-Soto J., Morales-González Á., Esquivel-Chirino C., Durante-Montiel I., Sánchez-Rivera G., Valadez-Vega C., Morales-González J. A., Inflammation, oxidative stress, and obesity. International Journal of Molecular Sciences 2011 12 5 3117 3132 2-s2.0-79957805810 10.3390/ijms12053117
60. Dimova E. Y., Samoylenko A., Kietzmann T., Oxidative stress and hypoxia: implications for plasminogen activator inhibitor-1 expression. Antioxidants and Redox Signaling 2004 6 4 777 791 2-s2.0-3042821937 10.1089/1523086041361596
61. Samarakoon R., Overstreet J. M., Higgins P. J., TGF-beta signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities. Cellular Signalling 2013 25 1 264 268
62. Sporn M. B., Liby K. T., NRF2 and cancer: the good, the bad and the importance of context. Nature Reviews Cancer 2012 12 564 571
63. Hotamisligil G. S., Inflammation and metabolic disorders. Nature 2006 444 7121 860 867 2-s2.0-33845866857 10.1038/nature05485
64. Lyon C. J., Hsueh W. A., Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. The American Journal of Medicine 2003 115 Supplement 1 8 62 68
65. Morange P. E., Alessi M. C., Verdier M., Casanova D., Magalon G., Juhan-Vague I., PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level. Arteriosclerosis, Thrombosis, and Vascular Biology 1999 19 5 1361 1365 2-s2.0-0032957071
66. Shimomura I., Funahashi T., Takahashi M., Maeda K., Kotani K., Nakamura T., Yamashita S., Miura M., Fukuda Y., Takemura K., Tokunaga K., Matsuzawa Y., Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nature Medicine 1996 2 7 800 803 2-s2.0-15844381594 10.1038/nm0796-800
67. Loskutoff D. J., Samad F., The adipocyte and hemostatic balance in obesity studies of PAI-1. Arteriosclerosis, Thrombosis, and Vascular Biology 1998 18 1 6
68. Ahn J., Lee H., Kim S., Ha T., Resveratrol inhibits TNF -induced changes of adipokines in 3T3-L1 adipocytes. Biochemical and Biophysical Research Communications 2007 364 4 972 977
69. Olholm J., Paulsen S. K., Cullberg K. B., Richelsen B., Pedersen S. B., Anti-inflammatory effect of resveratrol on adipokine expression and secretion in human adipose tissue explants. International Journal of Obesity 2010 34 1546 1553
70. Yen G. C., Chen Y. C., Chang W. T., Hsu C. L., Effects of polyphenolic compounds on tumor necrosis factor- (TNF)-induced changes of adipokines and oxidative stress in 3T3-L1 adipocytes. Journal of Agricultural and Food Chemistry 2011 59 2 546 551
71. Rosenow A., Noben J. P., Jocken J., Kallendrusch S., Fischer-Posovszky P., Mariman E. C., Renes J., Resveratrol-induced changes of the human adipocyte secretion profile. Journal of Proteome Research 2012 11 9 4733 4743 10.1021/pr300539b
72. Dolinsky V. W., Dyck J. R. B., Calorie restriction and resveratrol in cardiovascular health and disease. Biochimica et Biophysica Acta 2011 1812 11 1477 1489 2-s2.0-80053456372 10.1016/j.bbadis.2011.06.010
73. Speakman J. R., Mitchell S. E., Caloric restriction. Molecular Aspects of Medicine 2011 32 3 159 221 2-s2.0-80054690858 10.1016/j.mam.2011.07.001
74. Szkudelska K., Szkudelski T., Resveratrol, obesity and diabetes. European Journal of Pharmacology 2010 635 1-3 1 8 2-s2.0-77952321187 10.1016/j.ejphar.2010.02.054
75. Howitz K. T., Bitterman K. J., Cohen H. Y., Lamming D. W., Lavu S., Wood J. G., Zipkin R. E., Chung P., Kisielewski A., Zhang L., Scherer B., Sinclair D. A., Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003 425 6954 191 196 2-s2.0-0141719702 10.1038/nature01960
76. Zhu X., Liu Q., Wang M., Liang M., Yang X., Xu X., Zou H., Qiu J., Activation of Sirt1 by resveratrol inhibits TNF induced inflammation in Fibroblasts. PLoS ONE 2011 6 10 2-s2.0-80055113353 10.1371/journal.pone.0027081 e27081
77. Lin Q. Q., Yan C. F., Lin R., Zhang J. Y., Wang W. R., Yang L. N., Zhang K. F., SIRT1 regulates TNF -induced expression of CD40 in 3T3-L1 adipocytes via NF- B pathway. Cytokine 2012 60 2 447 455
78. Hou X., Xu S., Maitland-Toolan K. A., Sato K., Jiang B., Ido Y., Lan F., Walsh K., Wierzbicki M., Verbeuren T. J., Cohen R. A., Zang M., SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. Journal of Biological Chemistry 2008 283 29 20015 20026 2-s2.0-50649112638 10.1074/jbc.M802187200
79. Zang M., Xu S., Maitland-Toolan K. A., Zuccollo A., Hou X., Jiang B., Wierzbicki M., Verbeuren T. J., Cohen R. A., Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 2006 55 8 2180 2191 2-s2.0-33749349202 10.2337/db05-1188
80. Salt I. P., Palmer T. M., Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation. Expert Opinion on Investigational Drugs 2012 21 8 1155 1167
81. Bijland S., Mancini S. J., Salt I. P., Role of AMP-activated protein kinase in adipose tissue metabolism and inflammation. Clinical Science 2013 124 491 507
82. Görlach A., Diebold I., Schini-Kerth V. B., Berchner-Pfannschmidt U., Roth U., Brandes R. P., Kietzmann T., Busse R., Thrombin activates the hypoxia-inducible factor-1 signaling pathway in vascular smooth muscle cells role of the p22phox-containing NADPH oxidase. Circulation Research 2001 89 1 47 54 2-s2.0-0035816732
83. Kang K. W., Lee S. J., Kim S. G., Molecular mechanism of Nrf2 activation by oxidative stress. Antioxidants and Redox Signaling 2005 7 11-12 1664 1673 2-s2.0-28844469924 10.1089/ars.2005.7.1664
84. Ghanim H., Sia C. L., Korzeniewski K., Lohano T., Abuaysheh S., Marumganti A., Chaudhuri A., Dandona P., A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal. Journal of Clinical Endocrinology and Metabolism 2011 96 5 1409 1414 2-s2.0-79955675928 10.1210/jc.2010-1812
85. Morange P. E., Lijnen H. R., Alessi M. C., Kopp F., Collen D., Juhan-Vague I., Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arteriosclerosis, Thrombosis, and Vascular Biology 2000 20 4 1150 1154 2-s2.0-0034071531
86. Loskutoff D. J., Fujisawa K., Samad F., The fat mouse: a powerful genetic model to study hemostatic gene expression in obesity/NIDDM. Annals of the New York Academy of Sciences 2000 902 272 281
87. Pandey M., Loskutoff D. J., Samad F., Molecular mechanisms of tumor necrosis factor -mediated plasminogen activator inhibitor-1 expression in adipocytes. FASEB Journal 2005 19 10 1317 1319 2-s2.0-23444448101 10.1096/fj.04-3459fje
88. Gonzales A. M., Orlando R. A., Curcumin and resveratrol inhibit nuclear factor- B-mediated cytokine expression in adipocytes. Nutrition and Metabolism 2008 5, article 17
89. Kundu J. K., Surh Y., Molecular basis of chemoprevention by resveratrol: NF- B and AP-1 as potential targets. Mutation Research 2004 555 1-2 65 80 2-s2.0-5144223780 10.1016/j.mrfmmm.2004.05.019
90. Pfluger P. T., Herranz D., Velasco-Miguel S., Serrano M., Tschop M. H., Sirt1 protects against high-fat diet-induced metabolic damage. Proceedings of the National Academy of Sciences of the United States of America PNAS 2008 105 28 9793 9798
91. Yoshizaki T., Milne J. C., Imamura T., Schenk S., Sonoda N., Babendure J. L., Lu J., Smith J. J., Jirousek M. R., Olefsky J. M., SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Molecular and Cellular Biology 2009 29 5 1363 1374 2-s2.0-61749095297 10.1128/MCB.00705-08
92. Salminen A., Hyttinen J. M. T., Kaarniranta K., AMP-activated protein kinase inhibits NF- B signaling and inflammation: impact on healthspan and lifespan. Journal of Molecular Medicine 2011 89 7 667 676 2-s2.0-79959956336 10.1007/s00109-011-0748-0
93. Ozes O. N., Mayo L. D., Gustin J. A., Pfeffer S. R., Pfeffer L. M., Donner D. B., NF- B activation by tumour necrosis factor requires tie Akt serine-threonine kinase. Nature 1999 401 6748 82 85 2-s2.0-0033517189 10.1038/43466
94. Madrid L. V., Mayo M. W., Reuther J. Y., Baldwin A. S. Jr., Akt stimulates the transactivation potential of the RelA/p65 subunit of NF- B through utilization of the I B kinase and activation of the mitogen-activated protein kinase p38. Journal of Biological Chemistry 2001 276 22 18934 18940 2-s2.0-0035379555 10.1074/jbc.M101103200
95. Manna S. K., Mukhopadhyay A., Aggarwal B. B., Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF- B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. Journal of Immunology 2000 164 12 6509 6519 2-s2.0-0034660659
96. Heynekamp J. J., Weber W. M., Hunsaker L. A., Gonzales A. M., Orlando R. A., Deck L. M., Vander Jagt D. L., Substituted trans-stilbenes, including analogues of the natural product resveratrol, inhibit the human tumor necrosis factor alpha-induced activation of transcription factor nuclear factor B. Journal of Medicinal Chemistry 2006 49 24 7182 7189 2-s2.0-33845367887 10.1021/jm060630x
97. Nam N. H., Naturally occurring NF- B inhibitors. Mini-Reviews in Medicinal Chemistry 2006 6 945 951 10.2174/138955706777934937
98. Zhu J., Yong W., Wu X., Yu Y., Lv J., Liu C., Mao X., Zhu Y., Xu K., Han X., Liu C., Anti-inflammatory effect of resveratrol on TNF -induced MCP-1 expression in adipocytes. Biochemical and Biophysical Research Communications 2010 369 2 471 477
99. Kumar A., Sharma S. S., NF- B inhibitory action of resveratrol: a probable mechanism of neuroprotection in experimental diabetic neuropathy. Biochemical and Biophysical Research Communications 2010 394 2 360 365
100. Kim S., Jin Y., Choi Y., Park T., Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. Biochemical Pharmacology 2011 81 11 1343 1351 2-s2.0-79955611314 10.1016/j.bcp.2011.03.012